H1299 lung cancer cells were transfected with an empty vector, wild-type RET (RET) or KIF5B-RET expression plasmids and treated either with DMSO (serum) or vandetanib, as indicated...The anchorage-independent growth induced by KIF5B-RET was suppressed by treatment with vandetanib (<1 μM)...These results suggest that the RET fusions are a previously unidentified LADC driver mutation and a potential target for existing TKIs, including vandetanib...